324 related articles for article (PubMed ID: 32650408)
21. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
Basho RK; Yam C; Gilcrease M; Murthy RK; Helgason T; Karp DD; Meric-Bernstam F; Hess KR; Valero V; Albarracin C; Litton JK; Chavez-MacGregor M; Hong D; Kurzrock R; Hortobagyi GN; Janku F; Moulder SL
Oncologist; 2018 Nov; 23(11):1300-1309. PubMed ID: 30139837
[TBL] [Abstract][Full Text] [Related]
22. Mutant Phenotype p53 Immunohistochemical Expression Is Associated With Poor Prognostic Parameters and Disease-Free Survival in Triple-Negative Metaplastic Breast Carcinoma.
Hashmi AA; Sajid A; Hussain M; Zia S; Islam S; Diwan MA; Ali SM; Irfan M; Shamail F; Zia F
Cureus; 2021 May; 13(5):e15244. PubMed ID: 34188985
[TBL] [Abstract][Full Text] [Related]
23. A Unique Surgical Case of Mixed Metaplastic Breast Carcinoma With Heterologous Mesenchymal Differentiation and Conventional Adenocarcinomatous Elements.
Okanemasa Y; Shioya A; Kumagai M; Takata M; Tsubata Y; Han J; Terauchi T; Morioka E; Inokuchi M; Yamada S
Cureus; 2024 Mar; 16(3):e55926. PubMed ID: 38601424
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
Elfgen C; Reeve K; Moskovszky L; Güth U; Bjelic-Radisic V; Fleisch M; Tausch C; Varga Z
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2051-2059. PubMed ID: 31270600
[TBL] [Abstract][Full Text] [Related]
25. A comprehensive overview of metaplastic breast cancer: Features and treatments.
Yan Q; Deng Y; Zhang Q
Cancer Sci; 2024 May; ():. PubMed ID: 38735837
[TBL] [Abstract][Full Text] [Related]
26. A unique presentation of metaplastic breast carcinoma, NOS: A case report.
Mremi A; Mwakyembe TE; Suleman M; Lodhia J
Clin Case Rep; 2023 Dec; 11(12):e8320. PubMed ID: 38089485
[TBL] [Abstract][Full Text] [Related]
27. CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer.
Bartels S; van Luttikhuizen JL; Christgen M; Mägel L; Luft A; Hänzelmann S; Lehmann U; Schlegelberger B; Leo F; Steinemann D; Kreipe H
J Pathol; 2018 Jul; 245(3):373-383. PubMed ID: 29708279
[TBL] [Abstract][Full Text] [Related]
28. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
29. Subcellular localization of EZH2 phosphorylated at T367 stratifies metaplastic breast carcinoma subtypes.
McMullen ER; Skala SL; Gonzalez ME; Djomehri S; Chandrashekar DS; Varambally S; Kleer CG
Breast Cancer; 2021 Mar; 28(2):496-505. PubMed ID: 33247371
[TBL] [Abstract][Full Text] [Related]
30. Immunoprofile of metaplastic carcinomas of the breast.
Rakha EA; Coimbra ND; Hodi Z; Juneinah E; Ellis IO; Lee AH
Histopathology; 2017 May; 70(6):975-985. PubMed ID: 28029685
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic Features of Metaplastic Breast Carcinoma: Experience From a Tertiary Cancer Center of North India.
Damera VV; Chowdhury Z; Tripathi M; Singh R; Verma RK; Jain M
Cureus; 2022 Sep; 14(9):e28978. PubMed ID: 36237767
[TBL] [Abstract][Full Text] [Related]
32. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression.
Barnes PJ; Boutilier R; Chiasson D; Rayson D
Breast Cancer Res Treat; 2005 May; 91(2):173-8. PubMed ID: 15868445
[TBL] [Abstract][Full Text] [Related]
33. Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database.
Wang XX; Jiang YZ; Liu XY; Li JJ; Song CG; Shao ZM
Oncotarget; 2016 Apr; 7(16):22665-73. PubMed ID: 27009810
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological characteristics and prognosis of metaplastic carcinoma of the breast.
Xiao M; Yang Z; Tang X; Mu L; Cao X; Wang X
Oncol Lett; 2017 Aug; 14(2):1971-1978. PubMed ID: 28781640
[TBL] [Abstract][Full Text] [Related]
35. Metaplastic carcinoma of the breast with mesenchymal differentiation (carcinosarcoma). A unique presentation of an aggressive malignancy and literature review.
Salemis NS
Breast Dis; 2018; 37(3):169-175. PubMed ID: 29504519
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer.
Leo F; Bartels S; Mägel L; Framke T; Büsche G; Jonigk D; Christgen M; Lehmann U; Kreipe H
Virchows Arch; 2016 Aug; 469(2):191-201. PubMed ID: 27220763
[TBL] [Abstract][Full Text] [Related]
37. Axillary metaplastic breast carcinoma with ipsilateral pectoral invasive ductal carcinoma: an unusual presentation.
Zhang L; Comertpay S; Shimizu D; DeMay RM; Carbone M; Honda SA; Eaves JM
Case Rep Oncol Med; 2014; 2014():938509. PubMed ID: 25364575
[TBL] [Abstract][Full Text] [Related]
38. Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer.
Gorshein E; Matsuda K; Riedlinger G; Sokol L; Rodriguez-Rodriguez L; Eladoumikdachi F; Grandhi M; Ganesan S; Toppmeyer DL; Potdevin L; Toomey K; Hirshfield KM; Chan N
Case Rep Oncol; 2021; 14(2):931-937. PubMed ID: 34248561
[TBL] [Abstract][Full Text] [Related]
39. Metaplastic Breast Cancer: Mesenchymal Subtype Has Worse Survival Outcomes.
Özkurt E; Emiroğlu S; Cabioğlu N; Karanlık H; Önder S; Tükenmez M; İğci A; Özmen V; Müslümanoğlu M
Breast Care (Basel); 2022 Dec; 17(6):554-560. PubMed ID: 36590148
[TBL] [Abstract][Full Text] [Related]
40. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis.
Mills MN; Yang GQ; Oliver DE; Liveringhouse CL; Ahmed KA; Orman AG; Laronga C; Hoover SJ; Khakpour N; Costa RLB; Diaz R
Eur J Cancer; 2018 Jul; 98():48-58. PubMed ID: 29870876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
